Shopping Cart

Your shopping cart is currently empty

Miglustat

Name: Miglustat
Brand: TargetMol
SKU: T12039
Price: 38 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T12039Cas No. 72599-27-0

Alias OGT918, N-Butyldeoxynojirimycin, NB-DNJ

Miglustat (NB-DNJ) is an alkylated product of imino sugar deoxynojirimycin.It is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).

Miglustat

Copy Product Info

😃Good

Purity: 99.92%

Catalog No. T12039Alias OGT918, N-Butyldeoxynojirimycin, NB-DNJCas No. 72599-27-0

Miglustat (NB-DNJ) is an alkylated product of imino sugar deoxynojirimycin.It is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$38	In Stock	In Stock
5 mg	$89	In Stock	In Stock
10 mg	$139	In Stock	In Stock
25 mg	$258	In Stock	In Stock
50 mg	$428	In Stock	In Stock
100 mg	$623	-	In Stock
1 mL x 10 mM (in DMSO)	$98	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.92%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Miglustat AI Summary

Miglustat exhibits a broad range of bioactivities, characterized by its inhibitory action against various glycosidases and enzymes involved in carbohydrate metabolism and glucosylceramide synthesis. Specifically, it inhibits alpha-glucosidases such as those found in rat intestinal brush border membranes, with notable IC50 values for maltase (2100 nM), sucrase (58000 nM), and isomaltase (2700 nM). It also inhibits lysosomal alpha-glucosidase, Golgi alpha-mannosidase II, and other related enzymes in rat liver, with competitive inhibition noted for endoplasmic reticulum alpha-glucosidase II and Golgi alpha-mannosidase II. In mice, Miglustat influences glycosphingolipid levels and demonstrates an inhibitory effect on glucosylceramide synthase (IC50 = 50000 nM) and glucosylceramidase with an IC50 of 140 nM. It shows varying inhibitory effects on maltase, lactase, and sucrase, and has shown potential antiviral activities, including inhibition of HIV-1 induced cytopathogenicity in MT-4 and MOLT-4 cells, and activity against SARS-CoV-2. In human cell studies, Miglustat inhibits beta-glucocerebrosidase and activates beta-glucocerebrosidase mutants, suggesting potential therapeutic implications for Gaucher disease. The compound shows limited Hepatic side effects, with a Drug-Induced Liver Injury (DILI) severity class of 0.0, indicating no significant concerns for liver toxicity in the tested settings. Additionally, it has shown stability in recombinant human lysosomal alpha-glucosidase, which is beneficial for enzyme replacement therapies. The compound demonstrates moderate antiviral activities against Dengue virus and Bovine viral diarrhea virus with an EC50 of 100000 nM for both, and has also shown antifungal activity and anti-inflammatory effects in human cells. Despite these bioactivities, Miglustat exhibits no significant inhibition or binding affinity towards some cellular components and receptors, suggesting that its inhibitory actions are selective and context-dependent..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Miglustat (NB-DNJ) is an alkylated product of imino sugar deoxynojirimycin.It is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).
Synonyms	OGT918, N-Butyldeoxynojirimycin, NB-DNJ

Chemical Properties

Molecular Weight	219.28
Formula	C₁₀H₂₁NO₄
Cas No.	72599-27-0
Smiles	CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O
Relative Density.	1.234 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 130 mg/mL (592.85 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	4.5604 mL	22.8019 mL	45.6038 mL	228.0190 mL
5 mM	0.9121 mL	4.5604 mL	9.1208 mL	45.6038 mL
10 mM	0.4560 mL	2.2802 mL	4.5604 mL	22.8019 mL
20 mM	0.2280 mL	1.1401 mL	2.2802 mL	11.4009 mL
50 mM	0.0912 mL	0.4560 mL	0.9121 mL	4.5604 mL
100 mM	0.0456 mL	0.2280 mL	0.4560 mL	2.2802 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc